This company has been marked as potentially delisted and may not be actively trading. Cerecor (CERC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CERC vs. GMTX, CALT, ZYME, MENS, SBTX, MBX, AVTE, NLTX, CYBN, and BIOAShould you be buying Cerecor stock or one of its competitors? The main competitors of Cerecor include Gemini Therapeutics (GMTX), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Jyong Biotech (MENS), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), Cybin (CYBN), and BioAge Labs (BIOA). Cerecor vs. Its Competitors Gemini Therapeutics Calliditas Therapeutics AB (publ) Zymeworks Jyong Biotech Silverback Therapeutics MBX Biosciences Aerovate Therapeutics Neoleukin Therapeutics Cybin BioAge Labs Cerecor (NASDAQ:CERC) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability. Which has stronger earnings and valuation, CERC or GMTX? Cerecor has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Cerecor, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCerecor$6.70M95.87-$63.50M-$0.57-11.74Gemini TherapeuticsN/AN/A-$71.87M-$1.00-60.58 Do insiders & institutionals have more ownership in CERC or GMTX? 62.8% of Cerecor shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 45.7% of Cerecor shares are owned by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk and volatility, CERC or GMTX? Cerecor has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500. Does the media refer more to CERC or GMTX? In the previous week, Cerecor's average media sentiment score of 0.16 beat Gemini Therapeutics' score of 0.00 indicating that Cerecor is being referred to more favorably in the media. Company Overall Sentiment Cerecor Neutral Gemini Therapeutics Neutral Is CERC or GMTX more profitable? Gemini Therapeutics has a net margin of 0.00% compared to Cerecor's net margin of -1,194.82%. Gemini Therapeutics' return on equity of -38.78% beat Cerecor's return on equity.Company Net Margins Return on Equity Return on Assets Cerecor-1,194.82% -261.82% -133.96% Gemini Therapeutics N/A -38.78%-35.88% SummaryCerecor beats Gemini Therapeutics on 7 of the 11 factors compared between the two stocks. Get Cerecor News Delivered to You Automatically Sign up to receive the latest news and ratings for CERC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CERC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CERC vs. The Competition Export to ExcelMetricCerecorPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$642.30M$776.92M$5.70B$9.50BDividend YieldN/A4.84%4.60%4.01%P/E Ratio-11.741.4028.1020.05Price / Sales95.8725.35429.3789.38Price / CashN/A19.5636.2258.56Price / Book30.416.798.665.87Net Income-$63.50M-$4.32M$3.25B$258.55M Cerecor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CERCCerecorN/A$6.69+0.9%N/A-43.4%$642.30M$6.70M-11.7431GMTXGemini TherapeuticsN/A$59.38+2.8%N/A+36.0%$2.57BN/A-59.3830High Trading VolumeCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks2.5026 of 5 stars$14.32flat$21.00+46.6%+25.4%$997.86M$93.38M-9.55460Upcoming EarningsMENSJyong BiotechN/A$10.06-8.5%N/AN/A$764.84MN/A0.0031Quiet Period ExpirationSBTXSilverback TherapeuticsN/A$17.85-0.4%N/A+60.1%$643.64MN/A-7.3883High Trading VolumeMBXMBX Biosciences2.1297 of 5 stars$11.70-4.0%$37.57+221.1%N/A$391.06MN/A0.0036News CoverageAVTEAerovate TherapeuticsN/A$8.69-8.2%N/A-87.6%$251.88MN/A-2.9120High Trading VolumeNLTXNeoleukin TherapeuticsN/A$22.34-1.2%N/A-46.6%$209.95MN/A-7.1890High Trading VolumeCYBNCybin2.7149 of 5 stars$7.73-3.7%$85.00+999.6%N/A$177.98MN/A-1.7650BIOABioAge LabsN/A$4.76+3.5%N/AN/A$170.65M$1.45M0.00N/A Related Companies and Tools Related Companies Gemini Therapeutics Alternatives Calliditas Therapeutics AB (publ) Alternatives Zymeworks Alternatives Jyong Biotech Alternatives Silverback Therapeutics Alternatives MBX Biosciences Alternatives Aerovate Therapeutics Alternatives Neoleukin Therapeutics Alternatives Cybin Alternatives BioAge Labs Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CERC) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerecor Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cerecor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
